What is your preferred maintenance therapy in young, fit patients with de novo plasma cell leukemia who achieve complete response after autologous stem cell transplantation?

Topics: Hematologic Malignancies • Medical Oncology • Myeloma • Hematology

Answer from: Medical Oncologist at Academic Institution

Plasma cell leukemia is routinely excluded from post-transplant maintenance studies, so we cannot look to any of the randomized maintenance studies performed over the past decade. I would consider plasma cell leukemia to fit into the category of ultra-high risk myeloma, and would use lenalidomide pl...

Comments

Medical Oncologist at Uniformed Services University of the Health Sciences (USUHS)
Thank you. This patient received tandem autoSCT an...

Medical Oncologist at Cancer Care Specialists/Renown Oncology/UNR
No data for adding Dara. May try RVD or Ixazomib R...

Medical Oncologist at Alpine Hem/Onc
Agree, rev and proteosome inhibitor as Maintainenc...

Answer from: Medical Oncologist at Community Practice

If obtainable i would add daratumumab to VRD or VR ..No data but active. If stem cells left i would if fit enough do a second transplant

Comments

Medical Oncologist at Indiana University Simon Cancer Center
Agree that PCL should consider high risk and an IM...

Related Questions